Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ LawsuitTORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorde ...

Core Viewpoint - Quantum BioPharma Ltd. has announced the establishment of October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, linking potential future recoveries from ongoing litigation directly to shareholders [1][3]. Group 1: CVR Distribution Details - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds recovered from the Company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [2]. - Payments under the CVRs will only occur if the Company receives net proceeds from the litigation following a settlement or a final, non-appealable judgment, referred to as "Qualifying Net Proceeds" [2][4]. - The distribution date for the CVRs is currently undetermined and contingent upon the Company receiving Qualifying Net Proceeds from the litigation [5]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [6]. - The Company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of the unbuzzd™ product, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% [6]. - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [6].

Core Insights - Quantum BioPharma Ltd. has received two final reports related to its drug candidate Lucid-MS for Multiple Sclerosis, marking a significant milestone in its development process [1][2] - The reports will support the company's Investigational New Drug (IND) application to the US FDA for a Phase 2 clinical trial [1][2] - Lucid-MS is positioned as a first-in-class treatment targeting demyelination in Multiple Sclerosis [2] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3] - The company’s lead compound, Lucid-MS, is a patented new chemical entity that has shown potential in preventing and reversing myelin degradation in preclinical models [3] - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™ [3] Financial and Strategic Aspects - The agreement with Unbuzzd Wellness Inc. includes a royalty structure of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% indefinitely [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]

Core Viewpoint - Quantum BioPharma Ltd. held its annual general and special meeting of shareholders on September 26, 2025, where significant corporate governance decisions were made, including the election of directors and the re-appointment of auditors [1][2][3]. Shareholder Representation - At the AGSM, shareholders represented 100% of Class A Multiple Voting Shares and 46.352% of Class B Subordinate Voting Shares, with Class A shares providing 276,660 votes each [2]. Election of Directors - All nominees listed in the management information circular dated August 14, 2025, were elected as directors, with votes for each nominee exceeding 99% [3]. Auditor Re-appointment - MNP LLP was re-appointed as the Company's auditor with 99.588% of votes in favor, and the directors were authorized to fix the auditor's remuneration [4]. Class A Multiple Voting Shares Issuance - An ordinary resolution was passed allowing the Board to approve the issuance of up to 56 additional Class A Multiple Voting Shares until the next annual meeting, with 90.992% of votes in favor [4]. Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders, with drug candidates at various development stages [5][6]. Lead Compound Development - The Company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation associated with multiple sclerosis, showing promise in preclinical models [6]. Strategic Investments - Quantum BioPharma maintains a strategic investment portfolio through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial properties [6].

Core Viewpoint - Quantum BioPharma Ltd. announces a $5 million fundraising initiative through its licensee Unbuzzd Wellness Inc., which offers a scientifically-backed beverage aimed at enhancing alcohol metabolism and reducing hangover symptoms, without diluting existing shareholders [1][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][7]. - Unbuzzd Wellness Inc. is a public issuer that specializes in wellness and recovery supplements, particularly a beverage designed to aid in alcohol metabolism and cognitive recovery [4][7]. Product Details - Unbuzzd is a beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, developed by a team of experts in pharmacology and medicine [4][5]. - The product has undergone a clinical trial demonstrating significant efficacy, including a more than 40% faster reduction in blood alcohol concentration (BAC) within 30 minutes compared to control subjects [5]. Clinical Trial Findings - Key findings from the clinical trial include: - Accelerated alcohol metabolism with a significant reduction in BAC [5]. - Statistically significant improvements in alertness and cognitive performance within 30 minutes of consumption [5]. - Stabilization of heart rate and blood pressure during alcohol intoxication [5]. - Notable reduction in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [5][6]. - Unbuzzd was well-tolerated with no reported adverse side effects [6]. Investment Opportunity - Unbuzzd is hosting an investor webinar to discuss the investment opportunity related to its beverage and plans for scaling distribution and retail sales [2][3]. - The company aims to raise up to $5 million to support its expansion plans and potentially pave the way for an initial public offering [3]. Ownership and Financial Structure - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [7].

Core Insights - Quantum BioPharma Ltd. has received a Product License from Health Canada for its natural health product Qlarity, allowing it to sell the product in Canada [1][2][3] - Qlarity is designed to support energy production, metabolism, electrolyte balance, physical energy, motor performance, fatigue reduction, endurance, mental alertness, and cognitive performance [2][3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [4] - The company is advancing its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation associated with multiple sclerosis [4] - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which markets the dietary supplement unbuzzd™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [4]

Company Overview - Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [2] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical development [2] Analyst Coverage - Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a price target of US$45, contingent on successful Phase 2 and 3 trials of Lucid-MS between 2026 and 2028, with a commercial launch anticipated in 2029 [1] - The lead analyst for this report is Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners [1] Financial Interests - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is associated with the unbuzzd™ product, and is entitled to 7% royalty payments on sales until total payments reach $250 million, after which the royalty rate will decrease to 3% indefinitely [2]

Corporate Updates - Quantum BioPharma Ltd. is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][5] - The company has drug candidates at various stages of development, with a lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [5] Debt Settlement - On August 12, 2025, the company settled outstanding debt of $26,812.50 USD with a creditor by converting it into 1,102 Class B Shares at a price of $24.33 USD per share [2] Grant of Restricted Stock Units - On August 15, 2025, the company granted 800 restricted stock units (RSUs) each to two Clinical Advisors, Peter Stys and Jack Antel, with specific vesting conditions tied to regulatory filings [3][8] - The RSUs and Creditor Shares are subject to a statutory hold period of four months and one day [3] Advisory Board Changes - The company terminated the Board Advisor Agreement with Kevin Malone effective August 15, 2025, resulting in his departure from the advisory role [4] Strategic Investments - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the OTC version of its product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [5] - The company also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [5]

Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and has a portfolio of drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial property [4]